Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk

Research output: Contribution to journalComment/debate

Original languageEnglish
Pages (from-to)97-99
Number of pages3
JournalThe Lancet Diabetes and Endocrinology
Volume8
Issue number2
Early online date13 Dec 2019
DOIs
Publication statusPublished - 1 Feb 2020

Cite this

@article{5df81d58032e48dfb560989882fe8353,
title = "Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk",
author = "Bailey, {Clifford J.}",
year = "2020",
month = "2",
day = "1",
doi = "10.1016/S2213-8587(19)30414-0",
language = "English",
volume = "8",
pages = "97--99",
journal = "The Lancet Diabetes and Endocrinology",
issn = "2213-8587",
publisher = "Elsevier",
number = "2",

}

Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk. / Bailey, Clifford J.

In: The Lancet Diabetes and Endocrinology, Vol. 8, No. 2, 01.02.2020, p. 97-99.

Research output: Contribution to journalComment/debate

TY - JOUR

T1 - Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk

AU - Bailey, Clifford J.

PY - 2020/2/1

Y1 - 2020/2/1

UR - http://www.scopus.com/inward/record.url?scp=85078010259&partnerID=8YFLogxK

UR - https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858719304140?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2213858719304140%3Fshowall%3Dtrue&referrer=https:%2F%2Fpure.aston.ac.uk%2Fadmin%2Feditor%2Fdk%2Fatira%2Fpure%2Fapi%2Fshared%2Fmodel%2Fresearchoutput%2Feditor%2Fcontributiontojournaleditor.xhtml%3Fscheme%3D%26type%3D%26showMigrationIfUnknown%3Dtrue

U2 - 10.1016/S2213-8587(19)30414-0

DO - 10.1016/S2213-8587(19)30414-0

M3 - Comment/debate

C2 - 31843565

AN - SCOPUS:85078010259

VL - 8

SP - 97

EP - 99

JO - The Lancet Diabetes and Endocrinology

JF - The Lancet Diabetes and Endocrinology

SN - 2213-8587

IS - 2

ER -